Rankin Aubrey 4

4 · Revance Therapeutics, Inc. · Filed Aug 17, 2021

Form 4

Period: 2021-08-15

Director

Transactions

Tax Payment
Common Stock
[F1][F2]
2021-08-15$26.02/sh−4,949$128,773→ 74,827 total
Sale
Common Stock
[F3][F4]
2021-08-16$26.34/sh−9,364$246,659→ 65,463 total

Holdings

Footnotes (6)

[F1]Represents the number of shares withheld by and surrendered to the Issuer on August 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 57,251 shares. The RSA vests in three equal annual installments from August 15, 2020, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Inducement Plan (the "Plan")) on each vesting date.
[F2]The fair market value was determined on August 13, 2021 pursuant to the Plan.
[F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
[F4]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $26.71. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
[F6]These shares are held by The Rankin Irrevocable Trust, of which the children of Mr. Rankin are beneficiaries.

Signature

/s/ Dwight Moxie, Attorney-in-Fact|2021-08-17

Documents

1 file